Back to search results

NAD Supplementation for Brain Health in Aging

This study is looking at whether a form of Vitamin B3 called Nicotinamide riboside (NR) can improve brain health and memory in older adults. Researchers want to see if taking 1 gram of NR by mouth daily for 8 weeks can improve how well your brain's blood vessels work. You might be able to join if you are between 60 and 85 years old, can read and write in English, and have good enough hearing and vision to take part in tests. The study will measure changes in how your brain's blood vessels respond using special tests. The study plans to enroll 214 people, but its current status is unclear.

Study design
This interventional study plans to enroll 214 participants. You would either receive Nicotinamide riboside or a placebo (an inactive pill that looks the same).
What's involved
You would take a pill daily by mouth for 8 weeks. Your brain's blood vessel responses would be measured at 8 weeks.
Compensation
Not stated in the trial record.
Follow-up
Your brain's blood vessel responses will be measured at 8 weeks, which is when the treatment period ends.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05483465

The Effect of NAD Supplementation on Brain Vascular Health in Aging

Recruiting
PHASE4Ages 60–85Interventional
University of Oklahoma
~214 participants
Updated 2026-04-01 on ClinicalTrials.gov
What's tested:Nicotinamide ribosidePlacebo

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in neurovascular coupling using functional near infrared spectroscopy (fNIRS)
Measured over 8 weeks
+3 more outcomes measured

Conditions

Aging

Explore related trials

Aging

NCT05483465

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • University of Oklahoma Health Sciences Center

    Oklahoma City, Oklahomastudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Andriy Yabluchanskiy, MD, PhD · PRINCIPAL_INVESTIGATOR · University of Oklahoma

Who to contact

Andriy Yabluchanskiy, MD, PhD
[email protected]
405-271-7622
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age ≥60 and ≤85 years of age
Adequate hearing and visual acuity to participate in the examinations
Ability to read and write in English
Competence to provide informed consent.
Mini-Mental State Exam score ≥24

Exclusion

Vision or hearing impairment that would impair the ability to complete study assessments
Active CNS disease including multiple sclerosis, uncontrolled seizures, active brain cancer
Cerebrovascular accident other than TIA within 60 days prior to Visit 0
Major psychiatric disease, including major depression not currently controlled on medications, alcohol or drug abuse
Abnormal kidney function (creatinine \>2mg/dL or EGFR \<30mL/min) by most recent labs within 6 months prior to Visit 0
Elevated liver enzymes (AST and/or ALT above x2 upper limit of normal) by most recent labs within 6 months prior to Visit 0
Treatment with other NAD enhancers (Nicotinamide riboside or nicotinamide mononucleotide) within 4 weeks prior to randomization.
Any other medical condition which, in the opinion of investigator, would render the patient inappropriate or too unstable to complete the study protocol

What this trial measures

  • Change in neurovascular coupling using functional near infrared spectroscopy (fNIRS)8 weeks

    Functional near infrared spectroscopy (fNIRS) will be performed during the cognitive n-back task. fNIRS approach generates data that represent a relative change in oxygenated and deoxygenated hemoglobin measured over the cortical brain tissues. Neurovascular coupling will be evaluated as a change in oxy- and deoxy-hemoglobin between before and after treatment. Units of measure - beta. Reported as a %change from baseline, before and after treatment.

  • Change in neurovascular coupling using transcranial Doppler8 weeks

    Transcranial Doppler sonography will be used to measure the change in the blood flow velocities during the cognitive n-back task between before and after treatment. Units of measure - % change between the n-back tasks. Reported as a %change from baseline, before and after treatment.

  • Change in neurovascular coupling using the dynamic retinal vessel analysis8 weeks

    Flicker light-induced dilation of the retinal vessels (percentage increase over baseline diameter) will be measured in the right or left eye of each study participant using the Dynamic Vessel Analyzer (DVA, IMEDOS Systems, Jena, Germany). Units of measure mm, reported as a %change from baseline, before and after treatment.

  • Change in neuronal activity8 weeks

    EEG signal will be collected to generate spectral data. These data will be used for comparison of EEG activity between before and after treatment. Units of measure - power spectral density. Reported as a %change from baseline, before and after treatment.